BIOPAS, a leading and unique Latin American biopharmaceutical company focused on in-licensing and commercialization of specialty pharmaceuticals – to the exclusion of any generic and/or branded generic drugs – that address unmet medical needs in the region, announced today the full launch of its Brazilian operations with the exclusive distribution of RIVOTRIL® beginning in November, thus expanding its on-going strategic collaboration with CHEPLAPHARM ARZNEIMITTEL GmbH into the Brazilian territory.
Continue reading